The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced.
In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).
About this article
Cite this article
Shulman, D.S., Klega, K., Imamovic-Tuco, A. et al. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group. Br J Cancer 120, 869 (2019) doi:10.1038/s41416-019-0424-7